Developer docs
API playgroundTry for free, no card

Search company profiles

Resalis Therapeutics

Full company profile

uuid0000fpj

Namestring
Resalis Therapeutics
Legal namestring
Resalis Therapeutics S.r.l.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Resalis Therapeutics S.r.l. is a privately held, clinical-stage Italian biopharmaceutical company founded in 2021 and headquartered in Turin. The company develops non-coding RNA-based therapeutics targeting metabolic disorders, with a primary focus on obesity and metabolic associated fatty liver disease (MAFLD) including its progressive form MASH. The company's lead candidate, RES-010, is a locked nucleic acid (LNA) antisense oligonucleotide designed to inhibit microRNA-22 (miR-22), a regulator of lipid metabolism that the founders identified as dysregulated in obesity and fatty liver disease. By suppressing miR-22, RES-010 promotes metabolic rewiring toward higher energy expenditure, converts white adipose tissue into brown adipose tissue via UCP1 upregulation, and reduces hepatic steatosis and inflammation. A second-generation candidate, RES-020 (a GalNAc-conjugated form of RES-010), is in discovery stage.

The company's scientific foundation originates from Aalborg University's Center for RNA Medicine in Denmark and Harvard Medical School, where co-founders Riccardo Panella (CSO) and Sakari Kauppinen (CTO) — who previously supervised discovery of miravirsen, the world's first microRNA-targeted drug — established the underlying biology. The management team has been heavily augmented with senior pharma talent, including CEO Alessandro Toniolo (ex-Merck, Pfizer, Shire, Novartis), Chief Medical and Development Officer Almut Nitsche (17+ years at Sanofi in diabetes R&D), Chief Technical Development Officer Thomas Eichinger (33 years at Sanofi, former Global Head of CMC Dossiers), and Medical Director Sandor Batkai (former Cardior Pharmaceuticals co-founder, acquired by Novo Nordisk).

Resalis is pre-revenue and does not commercialize products. The business model anticipates future revenue through commercialization of RES-010 and pipeline products upon regulatory approval, likely via pharmaceutical partnership or licensing — as evidenced by Sanofi's strategic equity investment in October 2024. RES-010 entered Phase 1 clinical trials in December 2024, evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy in healthy, overweight, and moderately obese volunteers. The company targets two large, underserved patient populations: approximately 650 million people globally living with obesity (WHO data) and over 30% of the global population affected by MAFLD. To date, Resalis has raised approximately €26 million across seed and Series A rounds (Claris Ventures, Sunstone Life Science Ventures, Italian Angels for Growth, Club degli Investitori) plus the Sanofi strategic investment.

Short descriptiontext

Resalis Therapeutics is a clinical-stage Italian biotech developing RES-010, a first-in-class LNA antisense oligonucleotide that inhibits microRNA-22 to treat obesity and MAFLD/MASH. The company targets large metabolic disease populations with a disease-modifying subcutaneous therapy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTurin, Italy
HQ citystring
Turin
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antisense oligonucleotide therapeutics, RNA-based drug discovery, metabolic disease treatment, obesity therapeutics, microRNA inhibitors
Industry5 codes
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
RNA-based Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Expected to generate revenue through commercialization of RES-010 and future pipeline products upon regulatory approval. Pipeline includes first-generation RES-010 and second-generation RES-020 (GalNAc conjugated RES-010) targeting obesity and MAFLD/MASH.

resalistherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Resalis Therapeutics develops RNA-based drug candidates, primarily RES-010, an antisense oligonucleotide (ASO) using locked nucleic acid (LNA) technology to inhibit microRNA-22 (miR-22) for the treatment of metabolic disorders including obesity and metabolic associated fatty liver disease (MAFLD/MASH). The pipeline also includes RES-020, a GalNAc-conjugated second-generation formulation of RES-010. RES-010 is administered subcutaneously and is currently in Phase 1 clinical trials, with potential applications as standalone therapy or in combination with GLP-1 receptor agonists.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Preclinical studies demonstrated protection from obesity and fatty liver disease in mouse models
+2 more records
Product overview1 text field

Resalis Therapeutics is developing a pipeline of non-coding RNA-based drug candidates for metabolic diseases. The company's lead product is RES-010, an antisense oligonucleotide targeting miR-22 using LNA technology, currently in Phase 1 clinical trials for obesity and MAFLD/MASH. The second-generation candidate RES-020 is a GaINAc conjugated formulation of RES-010 in discovery stage. The company employs a dual indications strategy targeting both obesity and fatty liver disease with disease-modifying therapeutic potential.

Product and service2 records
1RES-010
CategoryAntisense Oligonucleotide Therapeutic
Description

RES-010 is an antisense oligonucleotide (ASO) drug candidate designed to specifically target and inhibit microRNA-22 (miR-22) using locked nucleic acid (LNA) technology. It is being developed for the treatment of obesity and metabolic associated fatty liver disease (MAFLD/MASH), administered via subcutaneous injection. The drug candidate restores regulation of lipid biosynthesis, promotes metabolic rewiring toward higher energy expenditure, transforms white adipose tissue into brown adipose tissue, and reduces hepatic steatosis and inflammation. Currently in Phase 1 clinical trials with potential for use as stand-alone therapy or in combination with GLP-1 receptor agonists.

2RES-020
CategoryAntisense Oligonucleotide Therapeutic
Description

RES-020 is a second-generation GalNAc-conjugated formulation of RES-010, designed to improve hepatocyte-targeted delivery and efficacy for metabolic disease treatment, currently in discovery stage.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Scientific roots originating from Aalborg University in Denmark. Co-founders Riccardo Panella and Sakari Kauppinen serve at the university. Panella serves as Associate Professor at Center for RNA Medicine, Department of Clinical Medicine. Kauppinen serves as Professor and Director of Center for RNA Medicine.

2Harvard Medical School
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Scientific roots originating from Harvard Medical School in the U.S. Co-founder Riccardo Panella conducted research at Beth Israel Deaconess Medical Center, part of Harvard Medical School.

resalistherapeutics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage microRNA-targeted therapeutics company. Most direct peer to Resalis given shared focus on microRNA inhibition as a therapeutic modality, including metabolic and renal programs.

TypeDirect peer
Description

Non-coding RNA-based therapeutics company in cardiovascular disease, acquired by Novo Nordisk. Resalis' Medical Director Sandor Batkai was co-founder there, and the company shares the same ncRNA therapeutic modality heritage.

TypeEmerging player
Description

MicroRNA therapeutics co-founded by Resalis' CTO Sakari Kauppinen. Closely related emerging player in the same non-coding RNA therapeutic space with overlapping scientific lineage.

TypeBroad incumbent
Description

Leading antisense oligonucleotide (ASO) platform company with multiple approved products. Broad incumbent in the ASO modality Resalis uses; relevant for chemistry/IP benchmarking and partnership signals.

TypeDirect peer
Description

Clinical-stage RNA therapeutics company using stereopure oligonucleotide chemistry across multiple disease areas. Direct comparable in modality (modified oligonucleotides) and stage.

TypeBroad incumbent
Description

Industry-leading RNAi therapeutics company (siRNA platform). Adjacent RNA-based therapeutic modality to ASOs, serving as a broad incumbent for RNA drug development risk/return benchmarks.

TypeDirect peer
Description

RNA therapeutics company developing Axiomer RNA editing platform for rare diseases. Comparable in RNA-based therapeutic modality and clinical-stage risk profile.

TypeDirect peer
Description

Commercial-stage MASH-focused company (resmetirom/Rezdiffra, first FDA-approved MASH therapy). Direct competitor in the MASH indication Resalis is pursuing, providing a benchmark for MASH development and commercialization.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing therapies for MASH. Direct peer in the MASH indication with similar stage profile and liver-targeted mechanism.

TypeDirect peer
Description

Clinical-stage MASH-focused company developing FGF21 analog pegozafermin. Comparable in stage and indication, representing a directly competitive clinical asset for the MASH opportunity.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Resalis Therapeutics

RNA-based Biopharmaceuticalsresalistherapeutics.com

Resalis Therapeutics is a clinical-stage Italian biotech developing RES-010, a first-in-class LNA antisense oligonucleotide that inhibits microRNA-22 to treat obesity and MAFLD/MASH. The company targets large metabolic disease populations with a disease-modifying subcutaneous therapy.

What Resalis Therapeutics does

Resalis Therapeutics S.r.l. is a privately held, clinical-stage Italian biopharmaceutical company founded in 2021 and headquartered in Turin. The company develops non-coding RNA-based therapeutics targeting metabolic disorders, with a primary focus on obesity and metabolic associated fatty liver disease (MAFLD) including its progressive form MASH. The company's lead candidate, RES-010, is a locked nucleic acid (LNA) antisense oligonucleotide designed to inhibit microRNA-22 (miR-22), a regulator of lipid metabolism that the founders identified as dysregulated in obesity and fatty liver disease. By suppressing miR-22, RES-010 promotes metabolic rewiring toward higher energy expenditure, converts white adipose tissue into brown adipose tissue via UCP1 upregulation, and reduces hepatic steatosis and inflammation. A second-generation candidate, RES-020 (a GalNAc-conjugated form of RES-010), is in discovery stage.

The company's scientific foundation originates from Aalborg University's Center for RNA Medicine in Denmark and Harvard Medical School, where co-founders Riccardo Panella (CSO) and Sakari Kauppinen (CTO) — who previously supervised discovery of miravirsen, the world's first microRNA-targeted drug — established the underlying biology. The management team has been heavily augmented with senior pharma talent, including CEO Alessandro Toniolo (ex-Merck, Pfizer, Shire, Novartis), Chief Medical and Development Officer Almut Nitsche (17+ years at Sanofi in diabetes R&D), Chief Technical Development Officer Thomas Eichinger (33 years at Sanofi, former Global Head of CMC Dossiers), and Medical Director Sandor Batkai (former Cardior Pharmaceuticals co-founder, acquired by Novo Nordisk).

Resalis is pre-revenue and does not commercialize products. The business model anticipates future revenue through commercialization of RES-010 and pipeline products upon regulatory approval, likely via pharmaceutical partnership or licensing — as evidenced by Sanofi's strategic equity investment in October 2024. RES-010 entered Phase 1 clinical trials in December 2024, evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy in healthy, overweight, and moderately obese volunteers. The company targets two large, underserved patient populations: approximately 650 million people globally living with obesity (WHO data) and over 30% of the global population affected by MAFLD. To date, Resalis has raised approximately €26 million across seed and Series A rounds (Claris Ventures, Sunstone Life Science Ventures, Italian Angels for Growth, Club degli Investitori) plus the Sanofi strategic investment.

Resalis Therapeutics firmographics

Firmographics
Name
Resalis Therapeutics
Legal name
Resalis Therapeutics S.r.l.
Website
https://resalistherapeutics.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Resalis Therapeutics is a clinical-stage Italian biotech developing RES-010, a first-in-class LNA antisense oligonucleotide that inhibits microRNA-22 to treat obesity and MAFLD/MASH. The company targets large metabolic disease populations with a disease-modifying subcutaneous therapy.
Ownership category
akta.pro rank

Resalis Therapeutics industry classification

Industry
Product category
RNA-based Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Antisense oligonucleotide therapeutics
  • RNA-based drug discovery
  • Metabolic disease treatment
  • Obesity therapeutics
  • MicroRNA inhibitors

Where Resalis Therapeutics is headquartered

Location

Headquarters

HQ city
Turin
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

Resalis Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage biopharmaceutical company. Expected to generate revenue through commercialization of RES-010 and future pipeline products upon regulatory approval. Pipeline includes first-generation RES-010 and second-generation RES-020 (GalNAc conjugated RES-010) targeting obesity and MAFLD/MASH.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Resalis Therapeutics product offering

Product offering

Core offering

Resalis Therapeutics develops RNA-based drug candidates, primarily RES-010, an antisense oligonucleotide (ASO) using locked nucleic acid (LNA) technology to inhibit microRNA-22 (miR-22) for the treatment of metabolic disorders including obesity and metabolic associated fatty liver disease (MAFLD/MASH). The pipeline also includes RES-020, a GalNAc-conjugated second-generation formulation of RES-010. RES-010 is administered subcutaneously and is currently in Phase 1 clinical trials, with potential applications as standalone therapy or in combination with GLP-1 receptor agonists.

Product overview

Resalis Therapeutics is developing a pipeline of non-coding RNA-based drug candidates for metabolic diseases. The company's lead product is RES-010, an antisense oligonucleotide targeting miR-22 using LNA technology, currently in Phase 1 clinical trials for obesity and MAFLD/MASH. The second-generation candidate RES-020 is a GaINAc conjugated formulation of RES-010 in discovery stage. The company employs a dual indications strategy targeting both obesity and fatty liver disease with disease-modifying therapeutic potential.

Differentiator

Problem solved

Functional benefit

Products and services

  • RES-010 RES-010 is an antisense oligonucleotide (ASO) drug candidate designed to specifically target and inhibit microRNA-22 (miR-22) using locked nucleic acid (LNA) technology. It is being developed for the treatment of obesity and metabolic associated fatty liver disease (MAFLD/MASH), administered via subcutaneous injection. The drug candidate restores regulation of lipid biosynthesis, promotes metabolic rewiring toward higher energy expenditure, transforms white adipose tissue into brown adipose tissue, and reduces hepatic steatosis and inflammation. Currently in Phase 1 clinical trials with potential for use as stand-alone therapy or in combination with GLP-1 receptor agonists.
  • RES-020 RES-020 is a second-generation GalNAc-conjugated formulation of RES-010, designed to improve hepatocyte-targeted delivery and efficacy for metabolic disease treatment, currently in discovery stage.

Quantifiable outcome

  • Preclinical studies demonstrated protection from obesity and fatty liver disease in mouse models
  • +2 more outcomes

Companies that use Resalis Therapeutics

Customer profile

Segments3 records

Ideal customer profiles3 records

Resalis Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Resalis Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Aalborg UniversitycoreStrategic or Co-development PartnerScientific roots originating from Aalborg University in Denmark. Co-founders Riccardo Panella and Sakari Kauppinen serve at the university. Panella serves as Associate Professor at Center for RNA Medicine, Department of Clinical Medicine. Kauppinen serves as Professor and Director of Center for RNA Medicine.
  • Harvard Medical SchoolminorStrategic or Co-development PartnerScientific roots originating from Harvard Medical School in the U.S. Co-founder Riccardo Panella conducted research at Beth Israel Deaconess Medical Center, part of Harvard Medical School.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Resalis Therapeutics competitors and assessment

Company assessment

Direct peers

  • Regulus Therapeutics: Clinical-stage microRNA-targeted therapeutics company. Most direct peer to Resalis given shared focus on microRNA inhibition as a therapeutic modality, including metabolic and renal programs.
  • Cardior Pharmaceuticals: Non-coding RNA-based therapeutics company in cardiovascular disease, acquired by Novo Nordisk. Resalis' Medical Director Sandor Batkai was co-founder there, and the company shares the same ncRNA therapeutic modality heritage.
  • Wave Life Sciences: Clinical-stage RNA therapeutics company using stereopure oligonucleotide chemistry across multiple disease areas. Direct comparable in modality (modified oligonucleotides) and stage.
  • ProQR Therapeutics: RNA therapeutics company developing Axiomer RNA editing platform for rare diseases. Comparable in RNA-based therapeutic modality and clinical-stage risk profile.
  • Madrigal Pharmaceuticals: Commercial-stage MASH-focused company (resmetirom/Rezdiffra, first FDA-approved MASH therapy). Direct competitor in the MASH indication Resalis is pursuing, providing a benchmark for MASH development and commercialization.
  • Sagimet Biosciences: Clinical-stage biopharmaceutical company developing therapies for MASH. Direct peer in the MASH indication with similar stage profile and liver-targeted mechanism.
  • 89bio: Clinical-stage MASH-focused company developing FGF21 analog pegozafermin. Comparable in stage and indication, representing a directly competitive clinical asset for the MASH opportunity.

Emerging players

  • NEUmiRNA Therapeutics: MicroRNA therapeutics co-founded by Resalis' CTO Sakari Kauppinen. Closely related emerging player in the same non-coding RNA therapeutic space with overlapping scientific lineage.

Broad incumbents

  • Ionis Pharmaceuticals: Leading antisense oligonucleotide (ASO) platform company with multiple approved products. Broad incumbent in the ASO modality Resalis uses; relevant for chemistry/IP benchmarking and partnership signals.
  • Alnylam Pharmaceuticals: Industry-leading RNAi therapeutics company (siRNA platform). Adjacent RNA-based therapeutic modality to ASOs, serving as a broad incumbent for RNA drug development risk/return benchmarks.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Resalis Therapeutics social profiles

Digital presence

Resalis Therapeutics compliance and trust

Trust signal

Compliance1 record

Resalis Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Resalis Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Resalis Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Resalis Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resalis Therapeutics

What does Resalis Therapeutics do?

Resalis Therapeutics develops RNA-based drug candidates, primarily RES-010, an antisense oligonucleotide (ASO) using locked nucleic acid (LNA) technology to inhibit microRNA-22 (miR-22) for the treatment of metabolic disorders including obesity and metabolic associated fatty liver disease (MAFLD/MASH). The pipeline also includes RES-020, a GalNAc-conjugated second-generation formulation of RES-010. RES-010 is administered subcutaneously and is currently in Phase 1 clinical trials, with potential applications as standalone therapy or in combination with GLP-1 receptor agonists.

Is Resalis Therapeutics a public or private company?

Resalis Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Resalis Therapeutics founded?

Resalis Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Resalis Therapeutics based?

Resalis Therapeutics is headquartered in Turin, Italy, in the Europe region.

How does Resalis Therapeutics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Resalis Therapeutics's main competitors?

Direct peers on record are Regulus Therapeutics, Cardior Pharmaceuticals, Wave Life Sciences, ProQR Therapeutics, Madrigal Pharmaceuticals, Sagimet Biosciences and 89bio. NEUmiRNA Therapeutics is listed as an emerging player. Broad incumbents are Ionis Pharmaceuticals and Alnylam Pharmaceuticals.

Does Resalis Therapeutics have an API?

No public API is recorded for Resalis Therapeutics.

What industry is Resalis Therapeutics in?

Resalis Therapeutics's product category is RNA-based Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialResalis Therapeutics Announces First-In-Human Data For RES-010 Demonstrating Safety And Tolerability With Early Weight Loss SignalsResalis Therapeutics announced topline data from its Phase 1a study of RES-010, a miR-22-targeting antisense oligonucleotide, in healthy overweight and obese participants. The study showed a favorable safety profile and early weight-loss signals, with Phase 1b data expected in H1 2027.GlobeNewswireResalis Therapeutics Announces First-in-Human Data for RES-010 Demonstrating Safety and Tolerability with Early Weight Loss SignalsResalis Therapeutics announced topline data from its first-in-human study of RES-010, a novel antisense oligonucleotide targeting miR-22. The Phase 1a study in 48 healthy volunteers showed a favorable safety profile and early weight-loss signals, with Phase 1b ongoing. Topline data from Phase 1b is expected in H1 2027.The Pharma LetterDiana Røpcke named Resalis CMOResalis Therapeutics appointed Diana Røpcke as chief medical officer. She will lead clinical strategy for RES-010, a non-coding RNA-targeted obesity therapy, in a Phase Ib study assessing weight loss and safety in overweight and obese participants.BioSpaceResalis Therapeutics Appoints Diana M. Røpcke as Chief Medical OfficerResalis Therapeutics appointed Diana M. Røpcke as Chief Medical Officer, who will lead clinical strategy for RES-010, a microRNA-based therapy in Phase 1b for weight loss. The drug targets metabolic drivers of obesity, and Røpcke previously led clinical development at Novo Nordisk.GlobeNewswireResalis Announces Initiation of Phase 1b Clinical StudyResalis Therapeutics announced the dosing of the first participant in a Phase 1b clinical study of RES-010, a novel antisense oligonucleotide targeting microRNA-22 for obesity treatment, at a single site in Australia. The randomized, placebo-controlled study will enroll up to 36 overweight and obese participants receiving once-weekly subcutaneous injections over 12 weeks, with topline data expected in late 2026. The company highlights that RES-010 is designed to deliver fat-selective weight loss while preserving lean muscle mass, differentiating it from existing GLP-1 medicines that do not address underlying disease drivers and often result in lean mass loss and rebound after discontinuation.GlobeNewswireResalis Therapeutics Appoints Sandor Batkai as Medical DirectorResalis Therapeutics appointed Sandor Batkai as Medical Director, effective January 22. He will oversee clinical development of RES-010, an antisense oligonucleotide targeting miR-22 for obesity, currently in Phase 1. Final Phase 1 data is expected this year, with a Phase 1b extension planned.GlobeNewswireResalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry MeetingsResalis Therapeutics presented preclinical data on RES-010, an antisense oligonucleotide targeting miR-22, at multiple meetings. In non-human primates, RES-010 monotherapy reduced fat mass by 15% versus 16% with semaglutide, and combination therapy achieved 33% fat reduction. The company plans to confirm the profile in its ongoing Phase 1 trial.Labiotech.euSeven miRNA-focused companies pioneering new therapies in 2024Seven miRNA-focused biotech companies are advancing therapies in 2024, including aceRNA, ARTHEx, Biorchestra, Cardior, Ceria, Resalis, and TransCode. Their candidates target diseases like cancer, heart failure, and Alzheimer's, with some in phase 1/2 trials. The global miRNA market is projected to grow from $1.58 billion in 2023 to $3.64 billion by 2030.FinSMEsResalis Therapeutics Raises €10M in Series A FundingResalis Therapeutics raised €10 million in a Series A funding round led by Sunstone Life Science Ventures. The company intends to use the capital to initiate and complete its first-in-human Phase 1 clinical trial for its lead obesity program, RES-010, aiming for Phase 2 readiness. This financing supports the progression of their non-coding RNA therapeutic approach into human trials scheduled for the first half of 2024.BioSpaceResalis Therapeutics Raises €10 Million Series A to Complete First Clinical Trial for RES-010 in ObesityResalis Therapeutics has closed a €10 million Series A financing round led by Sunstone Life Science Ventures to fund the first-in-human Phase 1 clinical trial for its obesity treatment candidate, RES-010. The proceeds will support the initiation of the trial in the first half of 2024 and prepare the program for Phase 2 readiness. This funding enables the company to advance its non-coding RNA-based compound, which aims to provide durable weight reduction and potential combination therapy benefits.